Latest Neurocrine Biosciences (NBIX) Headlines
Post# of 83
Posted On: 03/13/2014 12:08:45 AM
Latest Neurocrine Biosciences (NBIX) Headlines
Neurocrine Biosciences To Present At The 26th Annual Roth Conference
PR Newswire - Tue Mar 04, 1:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26th Annual Roth Conference in Laguna.
Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34th Annual Health Care Conference in Boston.
Neurocrine Biosciences prices public offering at USD17.75 per share
M2 - Thu Feb 27, 5:17AM CST
US-based drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Wednesday that it has priced its public offering of 8m shares of its common stock at USD17.75 per share.
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
PR Newswire - Wed Feb 26, 8:12PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $142 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
Digirad Corporation Reports Fourth Quarter and Year-End Financial Results
GlobeNewswire - Wed Feb 26, 5:00AM CST
Digirad Corporation (Nasdaq
RAD) today reported fourth quarter earnings of $0.8 million, or $0.04 per diluted share, with total revenues of $12.5 million. Ending cash, cash equivalents and available-for-sale securities was $26.4 million.
Neurocrine Biosciences proposes public offering of 7m common shares
M2 - Wed Feb 26, 3:06AM CST
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Tuesday that it plans to sell 7,000,000 shares of its common stock in an underwritten public offering.
Directory of South & Central American Libraries 2013
M2 - Wed Feb 26, 2:23AM CST
This new edition of the Directory of South & Central American Libraries provide essential details on all libraries throughout South and Central America including universities, public and special libraries and including the libraries of institutes and research centres.
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
PR Newswire - Tue Feb 25, 3:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Neurocrine will also grant to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock. Jefferies LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Neurocrine Biosciences Announces NBI-98854 Scientific Presentations at the International Parkinson and Movement Disorder Society's 18th Annual Congress
PR Newswire - Tue Feb 25, 6:30AM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders, to be held June 8-12, 2014 in Stockholm Sweden. This annual meeting draws over 5,000 experts from around the world to address current topics related to movement disorders.
Neurocrine Biosciences To Present At The Leerink Global Healthcare Conference
PR Newswire - Fri Feb 07, 9:00AM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Leerink Global Healthcare Conference in New York City.
Neurocrine Biosciences Reports Fourth Quarter And Year End 2013 Results
PR Newswire - Thu Feb 06, 3:01PM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2013.
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2013 Financial Results
PR Newswire - Tue Feb 04, 8:20AM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2013 financial results after the Nasdaq market closes on Thursday, February 6, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, February 6, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?
Alex Planes, The Motley Fool - Motley Fool - Mon Jan 27, 11:15AM CST
One of the best things about being a long-term investor is that the law of gravity need not apply to good stocks -- what goes up doesn't necessarily have to come down. But some stocks can still fly too close to the sun, singing investors who bought...
Ameris Bancorp Announces 2013 Financial Results
PR Newswire - Thu Jan 23, 3:00PM CST
AMERIS BANCORP (NASDAQ-GS: ABCB), Moultrie, Georgia, today reported unaudited operating net income of $23.6 million for the year ended December 31, 2013, compared to $14.4 million in 2012. Operating net income excludes $3.6 million of after-tax merger charges from the Company's net income for 2013. On an operating basis, net income available to common shareholders increased 101% to $21.9 million and $0.90 per share in 2013, compared to $10.9 million and $0.46 per share in 2012.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 22, 4:05PM CST
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
at The Street - Tue Jan 21, 6:00AM CST
Biotech and drug stocks are up almost 9% to start 2014, trouncing the broader market averages.
Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders
at The Street - Tue Jan 14, 9:15AM CST
Stocks with insider trader activity include NDSN, FNSR, NUVA, DECK and NBIX
This Week in Biotech: Putting On a Clinic
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 11, 10:47AM CST
With the SPDR S&P Biotech Index up 61% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jan 11, 7:10AM CST
What a week for health-care investors! At least 17 health-care stocks experienced gains of more than 20% over the past few days. But three of those went up a lot more than just 20%. Here are the three most humongous health-care stocks of the week. ...
Neurocrine Biosciences To Present At The 26th Annual Roth Conference
PR Newswire - Tue Mar 04, 1:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 26th Annual Roth Conference in Laguna.
Neurocrine Biosciences To Present At The Cowen And Company 34th Annual Health Care Conference
PR Newswire - Thu Feb 27, 6:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Cowen and Company 34th Annual Health Care Conference in Boston.
Neurocrine Biosciences prices public offering at USD17.75 per share
M2 - Thu Feb 27, 5:17AM CST
US-based drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Wednesday that it has priced its public offering of 8m shares of its common stock at USD17.75 per share.
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
PR Newswire - Wed Feb 26, 8:12PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a price to the public of $17.75 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neurocrine, are expected to be approximately $142 million. The offering is expected to close on or about March 4, 2014, subject to customary closing conditions. Neurocrine anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, including working capital.
Digirad Corporation Reports Fourth Quarter and Year-End Financial Results
GlobeNewswire - Wed Feb 26, 5:00AM CST
Digirad Corporation (Nasdaq
RAD) today reported fourth quarter earnings of $0.8 million, or $0.04 per diluted share, with total revenues of $12.5 million. Ending cash, cash equivalents and available-for-sale securities was $26.4 million. Neurocrine Biosciences proposes public offering of 7m common shares
M2 - Wed Feb 26, 3:06AM CST
Drug company Neurocrine Biosciences (NasdaqGS:NBIX) said on Tuesday that it plans to sell 7,000,000 shares of its common stock in an underwritten public offering.
Directory of South & Central American Libraries 2013
M2 - Wed Feb 26, 2:23AM CST
This new edition of the Directory of South & Central American Libraries provide essential details on all libraries throughout South and Central America including universities, public and special libraries and including the libraries of institutes and research centres.
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
PR Newswire - Tue Feb 25, 3:00PM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell 7,000,000 shares of its common stock in an underwritten public offering. In connection with this offering, Neurocrine will also grant to the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock. Jefferies LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for this offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Neurocrine Biosciences Announces NBI-98854 Scientific Presentations at the International Parkinson and Movement Disorder Society's 18th Annual Congress
PR Newswire - Tue Feb 25, 6:30AM CST
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that two NBI-98854 scientific abstracts have been accepted for the scientific program at the 2014 Annual Congress of Parkinson's Disease and Movement Disorders, to be held June 8-12, 2014 in Stockholm Sweden. This annual meeting draws over 5,000 experts from around the world to address current topics related to movement disorders.
Neurocrine Biosciences To Present At The Leerink Global Healthcare Conference
PR Newswire - Fri Feb 07, 9:00AM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences, will be presenting at the Leerink Global Healthcare Conference in New York City.
Neurocrine Biosciences Reports Fourth Quarter And Year End 2013 Results
PR Newswire - Thu Feb 06, 3:01PM CST
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter and year ended December 31, 2013.
Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2013 Financial Results
PR Newswire - Tue Feb 04, 8:20AM CST
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its fourth quarter and year-end 2013 financial results after the Nasdaq market closes on Thursday, February 6, 2014. Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update Thursday afternoon, February 6, 2014 at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?
Alex Planes, The Motley Fool - Motley Fool - Mon Jan 27, 11:15AM CST
One of the best things about being a long-term investor is that the law of gravity need not apply to good stocks -- what goes up doesn't necessarily have to come down. But some stocks can still fly too close to the sun, singing investors who bought...
Ameris Bancorp Announces 2013 Financial Results
PR Newswire - Thu Jan 23, 3:00PM CST
AMERIS BANCORP (NASDAQ-GS: ABCB), Moultrie, Georgia, today reported unaudited operating net income of $23.6 million for the year ended December 31, 2013, compared to $14.4 million in 2012. Operating net income excludes $3.6 million of after-tax merger charges from the Company's net income for 2013. On an operating basis, net income available to common shareholders increased 101% to $21.9 million and $0.90 per share in 2013, compared to $10.9 million and $0.46 per share in 2012.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 22, 4:05PM CST
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013
at The Street - Tue Jan 21, 6:00AM CST
Biotech and drug stocks are up almost 9% to start 2014, trouncing the broader market averages.
Insider Trading Alert - NDSN, FNSR, NUVA, DECK And NBIX Traded By Insiders
at The Street - Tue Jan 14, 9:15AM CST
Stocks with insider trader activity include NDSN, FNSR, NUVA, DECK and NBIX
This Week in Biotech: Putting On a Clinic
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 11, 10:47AM CST
With the SPDR S&P Biotech Index up 61% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
3 Humongous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Jan 11, 7:10AM CST
What a week for health-care investors! At least 17 health-care stocks experienced gains of more than 20% over the past few days. But three of those went up a lot more than just 20%. Here are the three most humongous health-care stocks of the week. ...
(0)
(0)Neurocrine Biosciences (NBIX) Stock Research Links
Scroll down for more posts ▼